A phase I trial of oral ETX 1153c in healthy volunteers.

Trial Profile

A phase I trial of oral ETX 1153c in healthy volunteers.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2013

At a glance

  • Drugs ETX 1153 (Primary)
  • Indications Clostridium infections
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Dec 2013 Status changed from planning to discontinued (e-Therapeutics is no longer planning to advance ETC 1153 into clinical development for C. difficile)
    • 22 Oct 2012 Planned initiation date changed to 1 Jun 2013, according to an e-Therapeutics media release.
    • 27 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top